| Novel ADCs and strategies to overcome resistance to anti-HER2 ADCs E Díaz-Rodríguez, L Gandullo-Sánchez, A Ocaña, A Pandiella Cancers 14 (1), 154, 2021 | 44 | 2021 |
| HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies L Gandullo‐Sánchez, E Capone, A Ocaña, S Iacobelli, G Sala, ... EMBO Molecular Medicine 12 (5), e11498, 2020 | 32 | 2020 |
| HER3 in cancer: from the bench to the bedside L Gandullo-Sánchez, A Ocaña, A Pandiella Journal of Experimental & Clinical Cancer Research 41 (1), 310, 2022 | 24 | 2022 |
| Adaptive resistance to trastuzumab impairs response to neratinib and lapatinib through deregulation of cell death mechanisms C Ríos-Luci, E Díaz-Rodríguez, L Gandullo-Sánchez, L Díaz-Gil, A Ocaña, ... Cancer Letters 470, 161-169, 2020 | 13 | 2020 |
| Therapy-induced senescence enhances the efficacy of HER2-targeted antibody–drug conjugates in breast cancer S Duro-Sánchez, M Nadal-Serrano, M Lalinde-Gutiérrez, EJ Arenas, ... Cancer research 82 (24), 4670-4679, 2022 | 11 | 2022 |
| Generation of antibody-drug conjugate resistant models L Gandullo-Sánchez, A Ocaña, A Pandiella Cancers 13 (18), 4631, 2021 | 8 | 2021 |
| JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic … H Aranda-Tavío, C Recio, P Martín-Acosta, M Guerra-Rodríguez, ... Biomedicine & Pharmacotherapy 144, 112330, 2021 | 7 | 2021 |
| An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs L Gandullo-Sánchez, A Pandiella Cancer Letters 554, 216024, 2023 | 5 | 2023 |
| Antitumoral activity of a CDK9 PROTAC compound in HER2-positive breast cancer MM Noblejas-López, L Gandullo-Sánchez, EM Galán-Moya, ... International Journal of Molecular Sciences 23 (10), 5476, 2022 | 5 | 2022 |
| Altered proTGFα/cleaved TGFα ratios offer new therapeutic strategies in renal carcinoma S García-Alonso, I Romero-Pérez, L Gandullo-Sánchez, L Chinchilla, ... Journal of Experimental & Clinical Cancer Research 40, 1-13, 2021 | 3 | 2021 |
| Cáncer de mama HER2+: mecanismos de resistencia a tratamientos dirigidos y nuevas dianas terapéuticas L Gandullo-Sánchez Universidad de Salamanca, 2021 | | 2021 |
| HER-3 targeting with an antibody-drug conjugate L Gandullo-Sánchez | | 2021 |
| Resumen de tesis. Cáncer de mama HER2+: mecanismos de resistencia a tratamientos dirigidos y nuevas dianas terapéuticas L Gandullo Sánchez | | 2021 |
| EV20/MMAF muestra actividad antitumoral potente y específica en cáncer de mama HER2 positivo L Gandullo-Sánchez, E Capone, E Díaz-Rodríguez, D D'Agostino, ... | | 2018 |
| Targeting trastuzumab and T-DM1 resistant breast cancer cells with EV20/MMAF, an Antibody-Drug Conjugated against HER-3 L Gandullo-Sánchez, E Capone, E Díaz-Rodríguez, D D'Agostino, ... | | 2018 |
